FLT3 Inhibitors Impact Treatment Landscape for Patients With FLT3-Mutated AML
September 18th 2019Gail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.
Watch
NGS Testing Necessary for Treatment of Lung Adenocarcinoma
September 17th 2019Timothy F. Burns, MD, PhD, discusses the necessary role of next-generation sequencing testing in patients with lung adenocarcinoma. In order to incorporate this into clinical practice, there is still a lot more work to be done, Burns says. Around 20% to 25% of patients with adenocarcinoma have targetable alterations.
Watch
Melflufen Plus Dexamethasone Safe and Effective For R/R Multiple Myeloma
September 15th 2019Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
Watch
Apalutamide Combination is Well Tolerated in Metastatic Castration-Sensitive Prostate Cancer
September 10th 2019Kim N. Chi, MD, discusses the safety findings for the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer, according to findings from the phase III TITAN study. This combination was compared with placebo and ADT and presented at the 2019 ASCO Annual Meeting.
Watch
Evaluating the Role of Liquid Biopsy in Breast Cancer
September 9th 2019Aditya Bardia, MBBS, MPH, discusses the value of liquid biopsies in the treatment landscape of breast cancer. The real value of liquid biopsy in this space lies in providing oncologists with insight on what’s happening in tumor evolution.
Watch